title: Effects of a short course of oral phosphate treatment on serum parathyroid hormone(1-84) and biochemical markers of bone turnover: a dose-response study.
abstract: To investigate the possible use of oral phosphate as an activator of bone remodeling in coherence treatment of osteoporosis, 82 postmenopausal females, aged 50-75 years, were randomized to treatment with oral phosphate (750, 1500, or 2550 mg/day) or placebo for 7 days and followed for 4 months thereafter. All patients had sustained at least one previous fracture of the distal forearm and had a bone mineral content of the contralateral forearm or bone mineral density of the lumbar spine lower than normal mean for age. Urinary phosphate/creatinine ratio increased in a dose-dependent fashion during treatment (P less than 0.001), whereas no significant changes were seen in serum phosphate or serum calcium. Serum parathyroid hormone (PTH) rose significantly (P less than 0.05) during treatment to a maximum of 36 and 33% in the groups receiving 1500 and 2250 mg/day, respectively, whereas serum 1,25-dihydroxycholecalciferol remained unchanged. In the group receiving 1500 mg/day, mean serum osteocalcin was increased in the period from day 1 to day 28 (P less than 0.05), but no significant changes were observed in urinary hydroxyproline/creatinine ratio, or serum bone alkaline phosphatase. We conclude that a short course of oral phosphate treatment increases serum PTH considerably. Furthermore, 1500 mg/day but not 2250 mg/day increases serum osteocalcin. No clear biochemical evidence, however, of increased activation of bone remodeling could be demonstrated in either group.
authors.affiliation: University Department of Endocrinology and Metabolism, Aarhus County Hospital, Denmark.
authors.forename: K
authors.initials: K
authors.lastname: Brixen
authors.forename: H K
authors.initials: HK
authors.lastname: Nielsen
authors.forename: P
authors.initials: P
authors.lastname: Charles
authors.forename: L
authors.initials: L
authors.lastname: Mosekilde
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000704:Analysis of Variance; D016723:Bone Remodeling / Q000187:drug effects*; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000652:urine; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood*; D010710:Phosphates / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology* / Q000652:urine; D011863:Radioimmunoassay
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; D015675:Osteocalcin; D003404:Creatinine; D002117:Calcitriol; D002118:Calcium